Key terms
About OPTN
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest OPTN news
Apr 25
9:03am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 26
8:45am ET
Lake Street Remains a Buy on Optinose (OPTN)
Mar 22
4:55am ET
Optinose management to meet virtually with Lake Street
Mar 19
11:14am ET
Optinose management to meet virtually with Lake Street
Mar 18
8:49am ET
Optinose price target raised to $4 from $3 at Lake Street
Mar 18
8:45am ET
Lake Street Sticks to Their Buy Rating for Optinose (OPTN)
Mar 18
7:00am ET
Analysts’ Top Healthcare Picks: Soleno Therapeutics (SLNO), Optinose (OPTN)
Mar 18
6:27am ET
Optinose’s XHANCE Expands Market Reach with FDA Label Extension: A Comprehensive Analysis
Mar 15
4:20pm ET
OptiNose trading resumes
Mar 15
3:52pm ET
OptiNose Inc: FDA Approval and Future Pediatric Study for XHANCE
Mar 15
3:45pm ET
Optinose to resume trading at 4:20 pm ET
Mar 15
3:36pm ET
Optinose says XHANCE nasal spray receives FDA approval
Mar 15
3:26pm ET
OptiNose trading halted, news pending
Mar 11
6:11am ET
Optinose initiated with a Buy at H.C. Wainwright
Mar 08
9:01am ET
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), IGM Biosciences (IGMS) and Optinose (OPTN)
Mar 07
7:08am ET
Optinose reports Q4 EPS (9c), consensus (9c)
Feb 23
7:22am ET
OptiNose Inc Secures New Lease with Initial Rent-Free Period
No recent press releases are available for OPTN
OPTN Financials
Key terms
Ad Feedback
OPTN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
OPTN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range